Gefitinib and erlotinib treatment of NSCLC patients harboring EGFR activating mutations and crizotinib treatment of NSCLC patients harboring activating ALK rearrangements are successful examples of this strategy [3], [4]. This evidence concerns the gene ALK and non-small cell lung carcinoma.